XellSmart Therapeutics (Shanghai) Co., Ltd. — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injectionThis Phase I clinical trial is designed to evaluate the safety, tolerability of a single dose of XS411 (derived dopaminergic neural progenitor cell injection) in patients with primary Parkinson's disease. This Phase II clinical trial is designed to evaluate the safety, tolerability and Efficacy of XS411 (derived dopaminergic neural progenitor cell injection) in patients with Parkinson's disease.	Parkinson	Phase 1/2	Thérapie cellulaire	China	À vérifier
human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injectionThis Phase I clinical trial is designed to evaluate the safety, tolerability of a single dose of XS411 (derived dopaminergic neural progenitor cell injection) in patients with primary Parkinson's disease. This Phase II clinical trial is designed to evaluate the safety, tolerability and Efficacy of XS411 (derived dopaminergic neural progenitor cell injection) in patients with Parkinson's disease.	Parkinson	Phase 1/2	Thérapie cellulaire	China	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection	Parkinson	Phase 1/2	NCT07080775	The Safety,Tolerability, Efficacy of XS411 Cell Injection for the Treatment of Primary Parkinson's Disease	ACTIVE_NOT_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.